Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients with Migraine: Three Cases

Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients with Migraine: Three Cases

A new treatment option for cluster headache (CH) prevention is needed. Monoclonal antibodies (mABs) against calcitonin gene-related peptide (CGRP) ligands are used as a preventative treatment for migraine. Considering the CGRP’s role in the CH attack’s ignition and upkeep, fremanezumab and galcanezu...

Full description

Bibliographic Details
Main Authors: Kenta Kashiwagi, Masahito Katsuki, Shin Kawamura, Senju Tachikawa, Atsuko Ono, Akihito Koh
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Neurology International
Subjects:
anti-calcitonin gene-related peptide monoclonal antibodies
cluster headache
migraine
real-world
galcanezumab
fremanezumab
Online Access:https://www.mdpi.com/2035-8377/15/1/20

Internet

https://www.mdpi.com/2035-8377/15/1/20

Similar Items